Genmab A/S (GMAB) |
|
44.4 0.28 (0.63%)
|
01-17 17:26 |
|
Open: |
43.32 |
Pre. Close: |
44.12 |
|
High:
|
44.83 |
Low:
|
43.11 |
|
Volume:
|
1,276,043 |
Market Cap:
|
28,767M |
|
|
|
|
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
44.884 - 45.056 |
45.056 - 45.229 |
|
Low:
|
42.662 - 42.866 |
42.866 - 43.071 |
|
Close:
|
44.066 - 44.383 |
44.383 - 44.701 |
|
Technical analysis |
as of: 2021-01-15 4:41:04 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 52.36  One year: 61.16 |
| Support: |
Support1: 40.78 Support2: 38.27 |
| Resistance: |
Resistance1: 44.83 Resistance2: 52.36 |
| Pivot: |
41.29 |
| Moving Average: |
MA(5): 42.89 MA(20): 40.95
MA(100): 37.67 MA(250): 31.74 |
| MACD: |
MACD(12,26): 1.28 Signal(9): |
| Stochastic oscillator: |
%K(14,3): 97.38 %D(3): 89.38 |
| RSI: |
RSI(14): 71.19 |
| 52-week: |
High: 44.83 Low: 16.24 Change(%): 96.6 |
| Average Vol(K): |
3-Month: 47672 10-Days: 56317 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.GMAB has closed above the upper band by 0.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 42.7% wider than normal. The large width of the bands suggest high volatility as compared to GMAB's normal range. The bands have been in this wide range for 0 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 15 Jan 2021
Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis - GlobeNewswire
Fri, 15 Jan 2021
First Week of March 19th Options Trading For Genmab (GMAB) - Nasdaq
Wed, 13 Jan 2021
Genmab A/S (GMAB) Achieves $40 Million Milestone in Collaboration with AbbVie - StreetInsider.com
Wed, 06 Jan 2021
Genmab to Present at the 39th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Tue, 05 Jan 2021
Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer | Antibodies | News Channels - PipelineReview.com
Tue, 05 Jan 2021
Genmab (GMAB) Begins Phase III Study on Cervical Cancer Drug - Yahoo Finance
|
Financial Analysis |
| Growth |
n/a |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
n/a |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
n/a |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Neutral |
Discounted cash flow: |
Neutral |
| Return on Assets: |
Neutral |
Price to Earnings: |
Neutral |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
655 |
| Shares Float (M) |
646 |
|
% Held by Insiders
|
|
|
% Held by Institutions
|
6.32 |
|
Shares Short (K)
|
595 |
|
Shares Short P. Month (K)
|
775 |
Stock Financials |
|
EPS
|
|
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
|
|
Profit Margin
|
51.22 |
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
27.3 |
|
Return on Equity (ttm)
|
36.5 |
|
Qtrly Rev. Growth
|
65.8 |
|
Gross Profit (p.s.)
|
8.193 |
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
|
|
Qtrly Earnings Growth
|
-1.30 |
|
Operating Cash Flow (M)
|
|
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
PE Ratio
|
|
|
PEG Ratio
|
2.48 |
|
Price to Book value
|
|
|
Price to Sales
|
|
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
